Impact of oral early antiviral therapies for mild–moderate COVID-19 in the outpatient’s setting during Omicron era: a pharmacoeconomic analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Impact of oral early antiviral therapies for mild–moderate COVID-19 in the outpatient’s setting during Omicron era: a pharmacoeconomic analysis ; volume:29 ; number:1 ; day:19 ; month:12 ; year:2024 ; pages:1-9 ; date:12.2024
European journal of medical research ; 29, Heft 1 (19.12.2024), 1-9, 12.2024
- Creator
-
Scaglione, Vincenzo
Gardin, Samuele
Sasset, Lolita
Presa, Nicolò
Rossetto, Alberto
Boemo, Deris Gianni
Silvola, Sofia
Restelli, Umberto
Cattelan, Annamaria
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40001-024-02154-2
- URN
-
urn:nbn:de:101:1-2503020600578.830004920745
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Scaglione, Vincenzo
- Gardin, Samuele
- Sasset, Lolita
- Presa, Nicolò
- Rossetto, Alberto
- Boemo, Deris Gianni
- Silvola, Sofia
- Restelli, Umberto
- Cattelan, Annamaria
- SpringerLink (Online service)
Other Objects (12)
Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors
5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro
The SARS-CoV-2 Omicron BA.1 spike G446S mutation potentiates antiviral T-cell recognition
Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes
Electrophysiological Profile of Different Antiviral Therapies in a Rabbit Whole-Heart Model
Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5
Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy
BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
Cardiovascular adverse effects of antiviral therapies for COVID-19: Evidence and plausible mechanisms
Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials
Omicron variant of SARS-CoV-2 exhibits an increased resilience to the antiviral type I interferon response
Omicron variant of SARS-CoV-2 exhibits an increased resilience to the antiviral type I interferon response
Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors
5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro
The SARS-CoV-2 Omicron BA.1 spike G446S mutation potentiates antiviral T-cell recognition
Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes
Electrophysiological Profile of Different Antiviral Therapies in a Rabbit Whole-Heart Model
Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5
Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy
BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
Cardiovascular adverse effects of antiviral therapies for COVID-19: Evidence and plausible mechanisms
Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials
Omicron variant of SARS-CoV-2 exhibits an increased resilience to the antiviral type I interferon response
Omicron variant of SARS-CoV-2 exhibits an increased resilience to the antiviral type I interferon response
Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors
5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro
The SARS-CoV-2 Omicron BA.1 spike G446S mutation potentiates antiviral T-cell recognition
Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes
Electrophysiological Profile of Different Antiviral Therapies in a Rabbit Whole-Heart Model
Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5
Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy
BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
Cardiovascular adverse effects of antiviral therapies for COVID-19: Evidence and plausible mechanisms
Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials
Omicron variant of SARS-CoV-2 exhibits an increased resilience to the antiviral type I interferon response